

TIMOTHY H. TWEITO, MD, FACS

CURRICULUM VITAE

EMPLOYMENT & ACADEMIC APPOINTMENTS

07/2021 – Present	Florida Retina Specialists Vitreoretinal Surgeon	Merritt Island, FL
08/2009 – 06/2021	Nevada Retina Center Vitreoretinal Surgeon	Las Vegas, NV
10/2007 – 04/2008	Seattle Supersonics Team Ophthalmologist	Seattle, WA
01/2007 – 05/2009	University of Washington Clinical Assistant Professor	Seattle, WA
08/2006 – 05/2009	Eye Associates Northwest, PC Vitreoretinal Surgeon	Seattle, WA
07/2004 – 06/2006	The Ohio State University Clinical Assistant Professor	Columbus, OH

EDUCATION

07/2004 – 06/2006	The Ohio State University Vitreoretinal Fellowship	Columbus, OH
07/2001 – 06/2004	The Ohio State University Ophthalmology Residency	Columbus, OH
07/2000 – 06/2001	University of Florida/Shands Hospital Internal Medicine Internship	Gainesville, FL
08/1996 – 06/2000	University of Kansas School of Medicine Doctorate of Medicine	Kansas City, KS
09/1991 – 06/1995	Northwestern University Bachelor of Science, Environmental Engineering	Evanston, IL

LICENSURE

02/2021 – Present	Florida Board of Medicine
08/2009 – Present	Nevada Board of Medicine

CERTIFICATION

11/2005	Board Certified by the American Board of Ophthalmology
---------	--

RESEARCH

Screening Ophthalmologist, Sangamo Bio Sciences, A Phase 2 Repeat Dosing Clinical Trial of SB-509 in Subjects with Diabetic Neuropathy.

Co-Investigator, Genentech, Phase III, Multicenter Randomized, Double-Masked, Sham Injection-Controlled Study of the Efficacy and Safety of rhuFab V2 (ranibizumab) in Subjects with Minimally Classis of Occult Subfoveal Neovascular Age-Related Macular Degeneration.

Co-Investigator, Genentech, A Phase IIIb, Multicenter Randomized, Double-Masked, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab in Subjects with Subfoveal Choroidal Neovascularization (CNV) with or without Classic CNV Secondary to Age-Related Macular Degeneration.

Co-Investigator, Genentech, An Open-Label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in subjects with Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) who have Completed the Treatment Phase of a Genentech Sponsored Ranibizumab Study

Tweito T, Abdel-Rahman M, Chorich U, Davidorf FH: Enucleation for Choroidal Melanoma. In Ryan, SJ, ed. Retina, 4th Edition. CV Mosby. In print.

Deasy R, Heverhagen J, Abdel-Rahman M, von Tengg-Kobligk H, Craig E, Gupta S, Jia G, Tweito T, Chambers RB, Knopp M, Davidorf FH: Evaluation of Choroidal Melanoma with Dynamic Contrast Enhanced MRI. Presented at the Ohio State University Post-Graduate Research Symposium, June 2005.

Tweito T, Kadari P, Abdel-Rahman M, Moldovan N, Davidorf FH: The Effect of Retinal Pigment Epithelial Cells on the Migration of Human Umbilical Vein Endothelial Cells. Presented at the Ohio State University Post-Graduate Research Symposium, June 2004.

HONORS & AWARDS

Makley-Battles Teaching Award

Ophthalmology Grand Round Award

Tau Beta Pi Engineering Honor Society

PROFESSIONAL MEMBERSHIPS

American Society of Retina Specialists

Fellow American College of Surgeons

American Academy of Ophthalmology

LANGUAGES

Fluent English and Spanish